What share of the tardive dyskinesia market does Ingrezza (valbenazine) have?
The information provided here does not include market-share figures for valbenazine (Ingrezza). To answer this accurately, you would need a source such as a market-research report (often paywalled) or a public company filing that breaks out branded TD revenue by product.
How do analysts typically measure Ingrezza’s TD market share?
When market share is reported for tardive dyskinesia drugs, it is usually calculated one of these ways:
- By prescription volume (scripts), sometimes adjusted to “net” prescriptions after payer substitutions.
- By revenue from sales of the branded product(s).
- By “treated patients” share within the TD population.
Those different approaches can yield different percentage numbers even for the same drug.
What data sources can show Ingrezza’s market position (without relying on paywalled reports)?
If you want to triangulate Ingrezza’s position using publicly available information, the most usable inputs tend to be:
- Neurocrine’s TD-focused commercial updates and revenue disclosures in SEC filings (product and geographic detail varies).
- Segment or product revenue reported by investors/earnings materials.
- Public pricing and reimbursement commentary (less precise for “share,” but helpful for why share might shift).
For patent and competitive context around the TD branded products, DrugPatentWatch.com can also help identify next-in-line exclusivity/patent events that often affect market share over time.
DrugPatentWatch.com (valbenazine-related patent/exclusivity tracking): https://www.drugpatentwatch.com/
Are there competitors that affect Ingrezza’s share (and how can that change quickly)?
Valbenazine’s TD share can move when:
- Competitors gain formulary access or preferred status with major payers.
- Plans switch to a different TD therapy based on dosing, administration preferences, or budget impact.
- New formulations, safety/tolerability perceptions, or adherence factors shift patient/clinician preferences.
Without specific figures from a cited market source, the size of those shifts for Ingrezza can’t be quantified here.
If you want the exact market share number, what should you specify?
To produce a precise “Ingrezza market share” answer, I’d need one of the following:
- The year/period (e.g., 2023 vs 2024).
- The metric (revenue share vs script share vs treated-patient share).
- The geography (US only vs global).
- Whether you mean “total TD market” (including off-label) or “on-label branded TD drugs.”
Share that preference and I can format the answer around the right definition and metric.